Glenmark Specialty, Hikma Pharma launch seasonal allergic rhinitis nasal spray in US
Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. have announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US.RYALTRIS is approved by the US Food and Drug Administration (USFDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in...
Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. have announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US.
RYALTRIS is approved by the US Food and Drug Administration (USFDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older.
For more details, check out the link given below:
Glenmark specialty, Hikma pharma launch seasonal allergic rhinitis nasal spray RYALTRIS in US
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd